Supplier
Racc Medical Associates LLC
Racc Medical Associates LLC was paid $11.34M by Medicaid between Jan 2018 and Dec 2024, across 78 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 53% of everything it billed.
33Billing provider infoRACC MEDICAL ASSOCIATES LLC
FORT WAYNE, IN 46804
FORT WAYNE, IN 46804
33aNPI1184976136assigned 10/15/2012
33bProvider typeDurable Medical Equipment & Medical Supplies
28Total paid$11.34M
24GClaims427,854
24DCodes billed78
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Durable Medical Equipment & Medical Supplies providers in Indiana
Rank by total paid#9 of 560
Median peer was paid$29.96
This provider vs. median378,414×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ROTH, DANIEL controls 14+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,790 | $268K | |
| 2019 | 44,549 | $866K | |
| 2020 | 46,257 | $974K | |
| 2021 | 75,046 | $1.42M | |
| 2022 | 68,053 | $2.23M | |
| 2023 | 85,816 | $3.02M | |
| 2024incomplete | 73,343 | $2.56M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 53% | 122,748 | 97,422 | $6.02M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 13% | 48,174 | 35,869 | $1.47M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 11% | 11,963 | 9,593 | $1.29M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 3.7% | 9,516 | 7,240 | $420K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 2.5% | 4,752 | 3,572 | $288K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.9% | 10,236 | 8,172 | $212K |
| 99443 | 1.5% | 10,933 | 9,143 | $174K | |
| 64635 | 1.4% | 1,628 | 1,148 | $156K | |
| 99406 | 1.0% | 15,372 | 12,718 | $115K | |
| 64483 | 1.0% | 1,616 | 1,307 | $114K | |
| 64493 | <1% | 1,287 | 844 | $86K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 8,124 | 6,587 | $82K |
66 more codes
| 64636 | <1% | 1,679 | $78K | |
| 99442 | <1% | 4,464 | $75K | |
| 81025 | <1% | 13,697 | $70K | |
| 27096 | <1% | 1,173 | $61K | |
| 64633 | <1% | 600 | $59K | |
| 64490 | <1% | 698 | $52K | |
| 64494 | <1% | 1,408 | $46K | |
| 62321 | <1% | 593 | $40K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 7,526 | $38K |
| 90833 | Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) | <1% | 3,174 | $35K |
| 77002 | <1% | 1,511 | $28K | |
| 64491 | <1% | 838 | $26K | |
| 80053 | Comprehensive metabolic panel | <1% | 7,746 | $26K |
| 64634 | <1% | 518 | $25K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,794 | $24K |
| 84439 | <1% | 7,738 | $23K | |
| 20610 | <1% | 1,387 | $22K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 8,621 | $21K |
| 36415 | Collection of venous blood by venipuncture | <1% | 8,434 | $16K |
| 62323 | <1% | 218 | $14K | |
| 82670 | <1% | 1,199 | $12K | |
| 62370 | <1% | 716 | $10K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 379 | $10K |
| 84144 | <1% | 1,203 | $9K | |
| 83001 | <1% | 1,202 | $8K | |
| 83002 | <1% | 1,203 | $8K | |
| 82570 | <1% | 34,258 | $6K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 128 | $5K |
| J3490 | Unclassified drugs | <1% | 169 | $5K |
| 95991 | <1% | 182 | $5K | |
| 76942 | <1% | 597 | $5K | |
| 83986 | <1% | 34,271 | $4K | |
| 64495 | <1% | 274 | $4K | |
| 84403 | <1% | 709 | $4K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 208 | $4K |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 582 | $3K |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 1,795 | $3K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 374 | $3K |
| 64492 | <1% | 171 | $3K | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 563 | $3K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 723 | $2K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 241 | $1K |
| 99205 | Prolong outpt/office vis | <1% | 33 | $1K |
| 64450 | <1% | 37 | $1K | |
| 99441 | <1% | 78 | $1K | |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 538 | $1K |
| 62369 | <1% | 49 | $572.93 | |
| 93041 | <1% | 186 | $460.47 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,098 | $426.79 |
| 73564 | <1% | 14 | $306.66 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 101 | $275.46 |
| 72100 | <1% | 13 | $244.50 | |
| 81001 | <1% | 828 | $149.17 | |
| 81003 | <1% | 552 | $116.22 | |
| 99484 | <1% | 36 | $115.78 | |
| 94761 | <1% | 268 | $95.65 | |
| 99416 | Prolong outpt/office vis | <1% | 31 | $66.16 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 3,517 | $36.86 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 398 | $24.98 |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 365 | $23.13 |
| 99415 | Prolong outpt/office vis | <1% | 31 | $3.70 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 2,395 | $0.00 |
| 99072 | 0% | 8,808 | $0.00 | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | 0% | 19 | $0.00 |
| 99070 | 0% | 86 | $0.00 | |
| 80050 | General health panel | 0% | 60 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROTH, DANIEL (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Mercy Management of Southeastern Pennsylvania | Darby, PA | $1.57M |
| Cox Barton County Hospital | Lamar, MO | $1.07M |
| Clifton Heights Fire Company | Clifton Heights, PA | $654K |
| Brookhaven Fire Company | Brookhaven, PA | $521K |
| The Darby Fire Company No 1 | Darby, PA | $471K |
| Union Fire Co 1 Amb Div | Oxford, PA | $331K |
| Dover Area Ambulance Club | Dover, PA | $256K |
| Yeadon Fire Co No 1 | Yeadon, PA | $217K |
| Folcroft Fire Company | Folcroft, PA | $128K |
| Concordville Fire and Protective Association | Concordville, PA | $78K |
| Briarcliffe Fire Company | Glenolden, PA | $70K |
| Longwood Fire Company | Kennett Square, PA | $44K |
| Cox Barton County Hospital | Golden City, MO | $21K |
| Racc Medical Associates LLC | Marion, IN | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.